A 14-week Pilot Prospective Clinical Trial With BiOkuris Product in Patients With Irritable Bowel Syndrome

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

116 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-11-23

Study Completion Date

2025-02-02

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Irritable Bowel Syndrome (IBS) is a common chronic gastrointestinal condition that affects approximately 10-20% of adults in Western countries. IBS is a disorder with chronic or recurrent colonic symptoms without a clear-cut etiology. This condition is characterized by chronic or recurrent ABDOMINAL PAIN, bloating, MUCUS in FECES, and an erratic disturbance of DEFECATION. Symptoms include cramping, abdominal pain, bloating, gas, and diarrhea or constipation, or both. Over 80% of individuals with IBS report food-related symptoms leading in the 70% of these patients to self-imposed food restrictions and/or modifications of their diet. These spontaneous unsupervised dietary modifications are associated with maladaptive eating patterns and unnecessary self-restricted diets, which could result in nutritional deficiencies.

BiOkuris product DDI-IBS-001 is a food multicomponents product based on BiOkuris proprietary chitin-glucan complex. The objectives of the VITABIOTIC study is to confirm the effectiveness of the DDI-IBS-001 product in improving global symptoms, abdominal pain, stool consistency, quality of life, anxiety and depression in IBS patients and to confirm the product's safety.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

The Effect of Probiotics on Symptoms and Intestinal Flora in Patients With Irritable Bowel Syndrome

NCT02108119

Irritable Bowel Syndrome

COMPLETED PHASE2

A Clinical Trial Evaluating Diets for IBS

NCT05831306

Irritable Bowel Syndrome

UNKNOWN NA

The Efficacy of Single-strain Probiotics in Patients With Irritable Bowel Syndrome

NCT05064930

Irritable Bowel Syndrome

COMPLETED NA

Effect of Bifidobacterium on Irritable Bowel Syndrome

NCT00737841

Irritable Bowel Syndrome

UNKNOWN NA

Effect of Lactobacillus Plantarum 299v on Symptoms of Irritable Bowel Syndrome

NCT01886781

Irritable Bowel Syndrome

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Irritable Bowel Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This is a prospective, randomized, double-blind, placebo controlled, multicenter, parallel group study. Patients will be recruited in multiple centers in Belgium.

Patients will be treated for a total of 12 weeks. The study consists of a 2 weeks run-in period followed by a 8 weeks treatment period with DDI-IBS-001. At the end of the 8 weeks treatment, patients will be divided in responders and non-responders based on their global symptoms' relief score (patients will be considered responders with a weekly SGA score mean of 3 points or less for at least 50% of the 6 last weeks of treatment before week 10 \[week 4 to 10\]).

Responder patients will be randomised in a 2:1 allocation ratio to receive either DDI-IBS-001 or placebo, for 4 additional weeks. Non-responder patients will continue the treatment with DDI-IBS-001 for additional 4 weeks. The study period will be followed by a follow-up period of 4 weeks during which patients will have free access to DDI-IBS-001.

Primary Study Purpose

OTHER

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

The stage 2 of this study is a double-blinded study. Neither patients, nor investigators, nor trial staff, nor the sponsor study team will be aware of treatment assignments prior to the database lock at the conclusion of the study. The study products are DDI-IBS-001 and its matching placebo. DDI-IBS-001 and placebo will be provided as sachets containing 1980mg of powder to be dissolved in a glass of water (about 250 ml) and taken orally, with the same composition except for the active ingredient.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Active arm - DDI-IBS-001

Group Type EXPERIMENTAL

DDI-IBS-001

Intervention Type DIETARY_SUPPLEMENT

The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.

Placebo arm

Group Type PLACEBO_COMPARATOR

DDDI-IBS-001 placebo

Intervention Type OTHER

The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DDI-IBS-001

The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 1.5 g/day. The product is a powder for oral administration 1x/day.

Intervention Type DIETARY_SUPPLEMENT

DDDI-IBS-001 placebo

The placebo product has the same composition in excipient, same form and same posology as DDI-IBS-001.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Adult females and males, aged 18-75 years,
2. Diagnosis of IBS at least 6 months prior to study entry,
3. Confirmed IBS according to Rome-IV criteria (as determined by investigator),
4. Patient having either constipation (IBS-C), diarrhoea (IBS-D) or alternance of constipation/diarrhoea (IBS-M),
5. Possession of a digital device (i.e., smartphone or tablet),
6. Patient who read, understood, and signed the informed consent form (ICF),
7. Patient willing to adhere to the study visit schedule and capable to understand and comply with protocol requirements and product intake,
8. Male, or female patient of childbearing potential, who agrees to use acceptable birth control methods throughout the study period.

As assessed at the end of the run-in period, week 2 :
9. Patient with a baseline score for abdominal pain ≥ 2 and \< 6 assessed on a 7-point Lickert scale
10. Patient with correct and complete reporting of the study questionnaires and scores during the run-in period (≥75% completion)

Exclusion Criteria

1. Severe gastrointestinal pathologies other than IBS, including: ulcers, coeliac disease, inflammatory bowel disease, bowel cancer, bowel resection, auto-immune diseases (e.g., rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, Graves' disease), bariatric surgery, acute or chronic diarrhoea secondary to confirmed infectious gastroenteritis, or enteral or parenteral nutrition,
2. Metabolic disorders affecting intestinal transit function or nutrient absorption including uncontrolled diabetes and uncontrolled dysthyroidism,
3. Patients experiencing complications of abdominal radiotherapy,
4. Surgical operations to the mouth or gastrointestinal tract within 4 weeks prior to study entry, or planned during the study; appendectomy within 6 months prior to study entry,
5. Galactose intolerance ,
6. Use of opioids or narcotic analgesics within 6 weeks prior to week 0,
7. Systemic antibiotic treatment in progress or prescribed less than 4 weeks prior to study entry,
8. Use of products marketed as or rich in prebiotics, probiotics, or symbiotics (e.g., kefir, probiotic yogurt, baker's yeast, etc.) less than 2 weeks prior to week 0,
9. Use of laxatives, antibloating agents, antidiarrheal medication, antispasmodics, anxiolytics, antidepressants, analgesics, and non-steroidals anti-inflammatory drugs if started less than 2 months prior to week 0 . These medications are authorized if consumed for longer than 2 months before week 0 and maintained at a stable dosage for the entire study duration,,
10. Diets including low-FODMAP, KETO/high-fat, gluten free/coeliac, paleo, weight loss, caloric restriction, low-carb, 5:2/whole day energy restriction, Atkins/high-protein, sugar-free, single-food, juicing/any day of juicing, any other restriction diet (e.g. very low calory), or vegan diets if started less than 2 months prior or stopped less than 1 month prior to week 0. These diets are authorized if followed for longer than 2 months before week 0 and maintained for the entire study duration,,
11. Excessive alcohol consumption (more than 10 units per week) and/or drug abuse,
12. Pregnancy and lactation, or plan to become pregnant during the study period,
13. Participation in other studies involving investigational or marketed products concomitantly or less than 3 months prior to study entry,
14. Known hypersensitivity to any of the ingredients or excipients of the investigational products,
15. Patient who has forfeited their freedom by administrative or legal award, or who is under guardianship or under limited judicial protection.

As assessed at the end of the run-in period, week 2 :
16. Use of opioids or narcotic analgesics during the run-in period (between week 0 and week 1),
17. Systemic antibiotic treatment in progress or prescribed during the run-in period (between week 0 and week 1),
18. Deviation from lifestyle and dietary recommendations to be followed during the study (between week 0 and week 1).

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No